sensitive to lysis by a CTL expressing a receptor recognized by the mAb (20, 21) . Thus, one can bypass the need for antigen or histocompatibility antigen recognition with an antibody-combining site. Finally, heteroconjugates of mAbs, one ofwhich recognizes the T-cell receptor, can focus a T cell to act at a site targeted by the other binding site of the bispecific heteroconjugate (20, 22) .
We have proposed that bispecific mAbs may be used in vivo for the therapeutic targeting of sites for T-cell attack.
One of the antibody sites should be anti-T-cell receptor and the other should be directed against a viral determinant expressed on infected cells or against a tumor-associated antigen. Chemical heteroconjugates of mAbs may be quickly removed from the circulation in vivo and may not readily access certain target sites. We report here that recombinant F(ab')2 dimers of mAbs produced by reduction/reoxidation and a true 7S hybrid antibody produced by a hybrid hybridoma cell line can efficiently target sites for attack by T cells.
The receptor on T cells that confers the specificity of their response to foreign antigen in association with a selfhistocompatibility antigen has recently been identified. Two chains, each of 40-50 kDa, called a and 13, form a disulfidebonded heterodimer. Both chains possess variable (V) and constant (C) regions that are encoded by separate V region, diversity (D) region, joining (J) region, and C region genes (1) (2) (3) (4) (5) . This heterodimer is noncovalently associated on the cell surface with three invariant polypeptides referred to as the T3 complex (6) (7) (8) .
Many different types of monoclonal antibodies (mAbs) have been raised against the T-cell receptor complex. Some of these react only with the particular T-cell clone used as immunogen-i.e., antiidiotypic (or anticlonotypic) mAbs (9) (10) (11) . A number of murine mAbs generated against human T-cell lines recognize 1-6% of human T cells (12, 13) . mAbs directed against an allotypic determinant expressed by one family of murine Vp regions react with about 20% of T cells in many inbred strains (14, 15) . Antibodies directed against the T3 complex react with all mature T cells (6) (7) (8) . All antibodies directed against the T-cell receptor-T3 complex can inhibit the function of T cells and, when insolubilizedon a bead, for example-can stimulate T-cell proliferation (10, 11, 16, 17) .
It has recently been shown that these same antireceptor mAbs can serve as target structures to focus T-cell activity at a certain site. The B-cell hybridomas producing mAbs against a cytotoxic T lymphocyte (CTL) receptor are sensitive targets for lysis by the CTL (18, 19 (23, 24) . Ascites fluid was produced in pristane-primed, irradiated (BALB/c x C57BL/6)F1 mice.
Abbreviations: CTL, cytotoxic T lymphocyte(s); mAb, monoclonal antibody.
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Production of the Hybrid Hybridoma. One of the subclones of F23.1 was found to be unable to grow in the hybridomaselective medium containing hypoxanthine, aminopterin, and thymidine (HAT medium). To select for this phenotype this line was carried for 2 weeks in medium containing 8-azaguanine. It was then subjected to increasing concentrations of ouabain, from 0.01 to 0.1 mM. Thus, we isolated a line of F23.1 that was HAT-sensitive and ouabain-resistant that continued to produce the mAb. This line was fused using polyethylene glycol to the 19E12 hybridoma (HAT-resistant, ouabain-sensitive) in a 1:1 ratio. One day following fusion, the cells were plated out in Costar 96-well microtiter plates in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, HAT, and 0.1 mM ouabain. Two weeks after plating, medium from growth-positive wells was tested for the presence of antibodies. KSH.4.38 is a rat/mouse hybridoma line expressing the F23.1 determinant that was used to test for the presence of this antibody (25 (28) . F(ab')2 fragments were purified by chromatography on protein A-Sepharose followed by a Sephacryl S-200 column and their purity was assayed by acrylamide gel electrophoresis. F(ab')2 fragments of both antibodies were reduced with 10 mM mercaptoethanol at pH 6.8 and the column-purified Fab' monomers were recombined at pH 8 under a stream of oxygen (29) . CTL Assay. One hundred microliters of serial dilutions of antibody preparations was placed in the wells of roundbottomed microtiter plates (Costar 3799). One hundred microliters of medium containing 1 x 104 Na251CrO4-labeled target cells (S.AKR or EL4) and 3 x 104 CTL clone (OE4 or OE25) was added to each well. Plates were incubated at 37°C for 4 hr and centrifuged, and 100 /4 of the supernatant was removed and assayed for radioactivity. Spontaneous release was measured by culturing labeled target cells in the absence of CTL. Total lysis was determined by using 1% Triton X-100. Percent specific release was calculated as 100 X (experimental release -spontaneous release)/(detergent release -spontaneous release).
RESULTS
Heteroconjugates of mAbs (one of which reacts with the T-cell receptor complex), formed with the bifunctional crosslinking reagent N-succinimydyl-3-(1-pyridyldithio)propionate, have been shown to focus T-cell activity at a target site identified by the other antibody (20, 22) . Chemical characterization of the heteroconjugates suggested that dimers and trimers of 7S antibodies could function in this way. To test whether a bivalent, bispecific antibody could focus T-cell activity, we produced recombinant F(ab')2 fragments and a hybrid hybridoma cell line that secretes a hybrid 7S antibody.
The anti-T-cell receptor mAb used in these studies was F23.1, a murine IgG2a that reacts with an allotypic determinant on -20% of T cells (15) . The targeting mAb used was 19E12, a murine IgG2a that reacts with the Thy-1.1 alloantigenic determinant (23, 24) . Two CTL clones from C57BL/6 mice specific for H-2d antigens were used, OE4 and OE25. The former expresses a T-cell receptor that reacts with F23.1. The targeted cell line S.AKR expresses Thy-1.1, whereas the control cell line EL4 expresses Thy-1.2.
The data in Fig. 1 shows that the unconcentrated culture medium of H1.10.1.6 is able to induce the lysis of S.AKR targets by OE4 effectors even at a 1:100 dilution. Ascites fluid of mice bearing the H1.10.1.6 cell line, which had been enriched for immunoglobulin by fractionation on protein A columns, was also very active in this test. The experiment reported in Fig. 3A shows that OE4 effector cells, but not OE25 effectors (which do not express the F23.1 determinant), are induced to lyse S.AKR targets by the H1.10.1.6 immunoglobulin. Both effector CTL are able to lyse S.AKR targets in the presence of a mitogenic lectin such as phytohemagglutinin (PHA) (Fig. 3B) . The data in Fig. 4A Fig. 5 . Three pools of the major peaks seen in Fig. 5A were made, concentrated, and rerun under the same conditions (Fig. S  B-D) . Peak I (Fig. SB) runs identically to F23.1 mAb, and peak III (Fig. SD) coincides with the 19E12 mAb. Peak II (Fig. SC) is thus the putative hybrid antibody. Functional evidence consistent with this suggestion is shown in Fig. 6 . Peak I has little activity in inducing lysis of S.AKR targets by OE4 CTL; peak III has some activity but on a weight basis is <1% as active as peak II. In accord with this, it is clear from the hydroxylapatite chromatography that peak III is somewhat contaminated with the material in peak II (Fig.  5D) . It is interesting to note that peak II can cause significant lysis of the S.AKR targets by a 3-fold excess of OE4 CTL at a protein concentration as low as 2 ng/ml. Chemical char- Immunology: Staerz acterization of the putative hybrid antibody peak from the hydroxylapatite column was performed by isoelectric focusing under nonreducing and reducing conditions (Fig. 7) . The starting mAbs, F23.1 and 19E12, are distinct by this technique (Fig. 7, lanes 1 and 2) . The HPLC-purified hybrid is quite unlike either parent under nonreducing conditions (Fig.  7A, 
DISCUSSION
In this paper we have described two methods of constructing bispecific antibodies that can target sites for attack by T cells. Both methods may be more useful for in vivo applications of T-cell focusing than constructing heteroconjugates of mAbs with chemical crosslinkers (20, 22) because of their longer survival in the circulation and better penetration to extravascular sites.
Recombinant F(ab')2 reagents have been constructed previously for applications in histochemical staining (30) . Two different antibody-producing cells have also been fused together previously, as in the original description of the hybridoma technology (31), myeloma-myeloma fusions (32) , and recently Milstein and Cuello have fused a hybridoma producing an antiperoxidase mAb with somatostatin immune spleen cells to produce a hybrid antibody useful in histochemistry (33, 34) .
We fused together two established hybridomas, one HATsensitive, ouabain-resistant, and the other HAT-resistant, ouabain-sensitive. The factors that affect the yield of the desired bispecific, hybrid antibody secreted by the hybrid hybridoma have been discussed (33, 34) homologous preference in LH pairing (35) . If this preference were absolute, and H-H pairing random, then the yield of the desired bispecific hybrid rises to 50% of the total immunoglobulin production. To maximize the chances of random H-H association, we deliberately chose parental antibodies of the same subclass, IgG2a. This probably made the physical separation of the parental and recombinant antibodies more difficult, and, indeed, the two parental immunoglobulins F23.1 and 19E12 were not separable by chromatofocusing or DEAE-Sephadex chromatography. However, the two were well resolved on hydroxylapatite chromatography (Fig. 5) . Since our electrophoretic analysis of the column fractions was not sufficient to estimate the degree of heterologous LH pairing, the middle peak from the chromatographic step, which contains the desired hybrid, may not be pure but may contain other, undesired species, such as L1H1-H2L, and other forms. We suspect that the actual yield of the desired hybrid is somewhere between 12.5% and 50% of total immunoglobulin production.
It is apparent from the titration of the targeting activity of the chromatographic pools shown in Fig. 6 that the hybrid hybridoma mAb is extremely efficient in this regard. Thus, a protein concentration of 2 ng/ml of pool II is sufficient, in a 4-hr assay, to cause the lysis of 30% ofthe targeted lymphoma cells, S.AKR, by the CTL clone OE4 at a CTL:target ratio of 3:1. It is also clear that the presence of the parental mAbs (F23.1, which binds the CTL receptor only, and 19E12, which binds only to the Thy-1.1 determinant on the target cell) does not efficiently inhibit the ability of the bispecific hybrid mAb to induce specific lysis of the targets. Thus, whole culture supernatant of H1.10.1.6 and the total, protein A-purified material from ascites fluids function in the targeting assay (Figs. 2-4) .
Future work must be directed toward assessing the in vivo applications of the hybrid antibody-targeting system. An AKR/J T-cell lymphoma that expresses Thy-1.1 can be titered for growth in AKR/Cum (Thy-1.2) host mice. If the tumor grows in and kills normal AKR/Cum mice, then effector T cells can be induced in the tumor-bearing mice with a strong antigenic challenge, such as a skin graft or a tumor graft of C57BL/6 (H-2b) origin. About 20% of the AKR/Cum anti-H-2b effector T cells express the F23.1 determinant and an attempt can be made to focus these cells on the AKR/J tumor by injecting the bispecific mAb F23.1/19E12. If the AKR/J tumor does .not grow in normal AKR/Cum hosts, then the recipients will have to be immunosuppressed and the induced, effector T cells given adoptively. Obviously, further applications of hybrid antibody targeting lie in focusing T cells to the site of a viral infection.
